Loading…

Development of an Intranasal In Situ System for Ribavirin Delivery: In Vitro and In Vivo Evaluation

Recently, ribavirin has demonstrated effectiveness in treating glioblastoma through intranasal administration utilizing the nose-to-brain delivery route. Enhancing ribavirin's bioavailability can be achieved by utilizing intranasal stimuli-responsive systems that create a gel on the nasal mucos...

Full description

Saved in:

Bibliographic Details
Published in:	Pharmaceutics 2024-09, Vol.16 (9), p.1125
Main Authors:	Mikhel, Iosif B, Bakhrushina, Elena O, Petrusevich, Danila A, Nedorubov, Andrey A, Appolonova, Svetlana A, Moskaleva, Natalia E, Demina, Natalia B, Kosenkova, Svetlana I, Parshenkov, Mikhail A, Krasnyuk, Jr, Ivan I, Krasnyuk, Ivan I
Format:	Article
Language:	English
Subjects:	Animal experimentation anticancer therapy Bioavailability Brain cancer Brain tumors cancer Cancer therapies Drug development Drug dosages Foreign bodies in situ systems Instrument industry intranasal administration Nose nose-to-brain mechanism Phase transitions Polymers Polysaccharides Ribavirin Tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by
cites
container_end_page
container_issue	9
container_start_page	1125
container_title	Pharmaceutics
container_volume	16
creator	Mikhel, Iosif B Bakhrushina, Elena O Petrusevich, Danila A Nedorubov, Andrey A Appolonova, Svetlana A Moskaleva, Natalia E Demina, Natalia B Kosenkova, Svetlana I Parshenkov, Mikhail A Krasnyuk, Jr, Ivan I Krasnyuk, Ivan I
description	Recently, ribavirin has demonstrated effectiveness in treating glioblastoma through intranasal administration utilizing the nose-to-brain delivery route. Enhancing ribavirin's bioavailability can be achieved by utilizing intranasal stimuli-responsive systems that create a gel on the nasal mucosa. The research examined thermosensitive, pH-sensitive, and ion-selective polymers in various combinations and concentrations, chosen in line with the current Quality by Design (QbD) approach in pharmaceutical development. Following a thorough assessment of key parameters, the optimal composition of gellan gum at 0.5%, Poloxamer 124 at 2%, and purified water with ribavirin concentration at 100 mg/mL was formulated and subjected to in vivo testing. Through experiments on male rats, the nose-to-brain penetration mechanism of the active pharmaceutical ingredient (API) was elucidated, showcasing drug accumulation in the olfactory bulbs and brain.
doi_str_mv	10.3390/pharmaceutics16091125
format	article
fullrecord	<record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_21faad652b6d403e958ace4327e26340</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A810779082</galeid><doaj_id>oai_doaj_org_article_21faad652b6d403e958ace4327e26340</doaj_id><sourcerecordid>A810779082</sourcerecordid><originalsourceid>FETCH-LOGICAL-d405t-c455889cec32793f65473409d36a72f4304a8d939ab4d7c6a713d81e04022d213</originalsourceid><addsrcrecordid>eNptUk1vEzEQXSEQrUJ_AmglLlxSbI_3w1xQ1RaIVAmJAldrYs-mjnbt4P2Q8u_rbQo0CPvg8fjNe5o3zrLXnJ0DKPZ-d4exQ0Pj4EzPS6Y4F8Wz7JQrpZZSCXj-JD7Jzvp-y9IC4DWol9kJqETDSzjNzBVN1IZdR37IQ5Ojz1d-iOixxzaF-a0bxvx23w_U5U2I-Te3xslF5_Mrat1Ecf9hhv10Qwyp2h4uU8ivJ2xHHFzwr7IXDbY9nT2ei-zHp-vvl1-WN18_ry4vbpZWsmJYGlkUda0MGRCVgqYsZAWSKQslVqKRwCTWVoHCtbSVSUkOtubEJBPCCg6LbHXgtQG3ehddh3GvAzr9kAhxozEmx1rSgjeItizEukziQKqok50yCZMok2ji-njg2o3rjqyh2ZT2iPT4xbs7vQmT5lxCwZLBi-zdI0MMv0bqB9253lDboqcw9ho4T3MTlZjF3v4D3YYx-uTVA6qcp1j_RW0wdeB8E5KwmUn1Rc1ZVSlWi4Q6_w8qbUudM8FT41L-qODN007_tPj7j8A9DD6-zw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3110649238</pqid></control><display><type>article</type><title>Development of an Intranasal In Situ System for Ribavirin Delivery: In Vitro and In Vivo Evaluation</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Mikhel, Iosif B ; Bakhrushina, Elena O ; Petrusevich, Danila A ; Nedorubov, Andrey A ; Appolonova, Svetlana A ; Moskaleva, Natalia E ; Demina, Natalia B ; Kosenkova, Svetlana I ; Parshenkov, Mikhail A ; Krasnyuk, Jr, Ivan I ; Krasnyuk, Ivan I</creator><creatorcontrib>Mikhel, Iosif B ; Bakhrushina, Elena O ; Petrusevich, Danila A ; Nedorubov, Andrey A ; Appolonova, Svetlana A ; Moskaleva, Natalia E ; Demina, Natalia B ; Kosenkova, Svetlana I ; Parshenkov, Mikhail A ; Krasnyuk, Jr, Ivan I ; Krasnyuk, Ivan I</creatorcontrib><description>Recently, ribavirin has demonstrated effectiveness in treating glioblastoma through intranasal administration utilizing the nose-to-brain delivery route. Enhancing ribavirin's bioavailability can be achieved by utilizing intranasal stimuli-responsive systems that create a gel on the nasal mucosa. The research examined thermosensitive, pH-sensitive, and ion-selective polymers in various combinations and concentrations, chosen in line with the current Quality by Design (QbD) approach in pharmaceutical development. Following a thorough assessment of key parameters, the optimal composition of gellan gum at 0.5%, Poloxamer 124 at 2%, and purified water with ribavirin concentration at 100 mg/mL was formulated and subjected to in vivo testing. Through experiments on male rats, the nose-to-brain penetration mechanism of the active pharmaceutical ingredient (API) was elucidated, showcasing drug accumulation in the olfactory bulbs and brain.</description><identifier>ISSN: 1999-4923</identifier><identifier>EISSN: 1999-4923</identifier><identifier>DOI: 10.3390/pharmaceutics16091125</identifier><identifier>PMID: 39339163</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animal experimentation ; anticancer therapy ; Bioavailability ; Brain cancer ; Brain tumors ; cancer ; Cancer therapies ; Drug development ; Drug dosages ; Foreign bodies ; in situ systems ; Instrument industry ; intranasal administration ; Nose ; nose-to-brain mechanism ; Phase transitions ; Polymers ; Polysaccharides ; Ribavirin ; Tumors</subject><ispartof>Pharmaceutics, 2024-09, Vol.16 (9), p.1125</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-2866-0049 ; 0009-0004-7170-8783 ; 0000-0002-9032-1558 ; 0000-0001-9337-5917 ; 0000-0002-7309-8913 ; 0000-0001-8557-8829 ; 0000-0001-8695-0346</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3110649238/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3110649238?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25744,27915,27916,37003,37004,38507,43886,44581,53782,53784,74173,74887</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39339163$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mikhel, Iosif B</creatorcontrib><creatorcontrib>Bakhrushina, Elena O</creatorcontrib><creatorcontrib>Petrusevich, Danila A</creatorcontrib><creatorcontrib>Nedorubov, Andrey A</creatorcontrib><creatorcontrib>Appolonova, Svetlana A</creatorcontrib><creatorcontrib>Moskaleva, Natalia E</creatorcontrib><creatorcontrib>Demina, Natalia B</creatorcontrib><creatorcontrib>Kosenkova, Svetlana I</creatorcontrib><creatorcontrib>Parshenkov, Mikhail A</creatorcontrib><creatorcontrib>Krasnyuk, Jr, Ivan I</creatorcontrib><creatorcontrib>Krasnyuk, Ivan I</creatorcontrib><title>Development of an Intranasal In Situ System for Ribavirin Delivery: In Vitro and In Vivo Evaluation</title><title>Pharmaceutics</title><addtitle>Pharmaceutics</addtitle><description>Recently, ribavirin has demonstrated effectiveness in treating glioblastoma through intranasal administration utilizing the nose-to-brain delivery route. Enhancing ribavirin's bioavailability can be achieved by utilizing intranasal stimuli-responsive systems that create a gel on the nasal mucosa. The research examined thermosensitive, pH-sensitive, and ion-selective polymers in various combinations and concentrations, chosen in line with the current Quality by Design (QbD) approach in pharmaceutical development. Following a thorough assessment of key parameters, the optimal composition of gellan gum at 0.5%, Poloxamer 124 at 2%, and purified water with ribavirin concentration at 100 mg/mL was formulated and subjected to in vivo testing. Through experiments on male rats, the nose-to-brain penetration mechanism of the active pharmaceutical ingredient (API) was elucidated, showcasing drug accumulation in the olfactory bulbs and brain.</description><subject>Animal experimentation</subject><subject>anticancer therapy</subject><subject>Bioavailability</subject><subject>Brain cancer</subject><subject>Brain tumors</subject><subject>cancer</subject><subject>Cancer therapies</subject><subject>Drug development</subject><subject>Drug dosages</subject><subject>Foreign bodies</subject><subject>in situ systems</subject><subject>Instrument industry</subject><subject>intranasal administration</subject><subject>Nose</subject><subject>nose-to-brain mechanism</subject><subject>Phase transitions</subject><subject>Polymers</subject><subject>Polysaccharides</subject><subject>Ribavirin</subject><subject>Tumors</subject><issn>1999-4923</issn><issn>1999-4923</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1vEzEQXSEQrUJ_AmglLlxSbI_3w1xQ1RaIVAmJAldrYs-mjnbt4P2Q8u_rbQo0CPvg8fjNe5o3zrLXnJ0DKPZ-d4exQ0Pj4EzPS6Y4F8Wz7JQrpZZSCXj-JD7Jzvp-y9IC4DWol9kJqETDSzjNzBVN1IZdR37IQ5Ojz1d-iOixxzaF-a0bxvx23w_U5U2I-Te3xslF5_Mrat1Ecf9hhv10Qwyp2h4uU8ivJ2xHHFzwr7IXDbY9nT2ei-zHp-vvl1-WN18_ry4vbpZWsmJYGlkUda0MGRCVgqYsZAWSKQslVqKRwCTWVoHCtbSVSUkOtubEJBPCCg6LbHXgtQG3ehddh3GvAzr9kAhxozEmx1rSgjeItizEukziQKqok50yCZMok2ji-njg2o3rjqyh2ZT2iPT4xbs7vQmT5lxCwZLBi-zdI0MMv0bqB9253lDboqcw9ho4T3MTlZjF3v4D3YYx-uTVA6qcp1j_RW0wdeB8E5KwmUn1Rc1ZVSlWi4Q6_w8qbUudM8FT41L-qODN007_tPj7j8A9DD6-zw</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Mikhel, Iosif B</creator><creator>Bakhrushina, Elena O</creator><creator>Petrusevich, Danila A</creator><creator>Nedorubov, Andrey A</creator><creator>Appolonova, Svetlana A</creator><creator>Moskaleva, Natalia E</creator><creator>Demina, Natalia B</creator><creator>Kosenkova, Svetlana I</creator><creator>Parshenkov, Mikhail A</creator><creator>Krasnyuk, Jr, Ivan I</creator><creator>Krasnyuk, Ivan I</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2866-0049</orcidid><orcidid>https://orcid.org/0009-0004-7170-8783</orcidid><orcidid>https://orcid.org/0000-0002-9032-1558</orcidid><orcidid>https://orcid.org/0000-0001-9337-5917</orcidid><orcidid>https://orcid.org/0000-0002-7309-8913</orcidid><orcidid>https://orcid.org/0000-0001-8557-8829</orcidid><orcidid>https://orcid.org/0000-0001-8695-0346</orcidid></search><sort><creationdate>20240901</creationdate><title>Development of an Intranasal In Situ System for Ribavirin Delivery: In Vitro and In Vivo Evaluation</title><author>Mikhel, Iosif B ; Bakhrushina, Elena O ; Petrusevich, Danila A ; Nedorubov, Andrey A ; Appolonova, Svetlana A ; Moskaleva, Natalia E ; Demina, Natalia B ; Kosenkova, Svetlana I ; Parshenkov, Mikhail A ; Krasnyuk, Jr, Ivan I ; Krasnyuk, Ivan I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d405t-c455889cec32793f65473409d36a72f4304a8d939ab4d7c6a713d81e04022d213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animal experimentation</topic><topic>anticancer therapy</topic><topic>Bioavailability</topic><topic>Brain cancer</topic><topic>Brain tumors</topic><topic>cancer</topic><topic>Cancer therapies</topic><topic>Drug development</topic><topic>Drug dosages</topic><topic>Foreign bodies</topic><topic>in situ systems</topic><topic>Instrument industry</topic><topic>intranasal administration</topic><topic>Nose</topic><topic>nose-to-brain mechanism</topic><topic>Phase transitions</topic><topic>Polymers</topic><topic>Polysaccharides</topic><topic>Ribavirin</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mikhel, Iosif B</creatorcontrib><creatorcontrib>Bakhrushina, Elena O</creatorcontrib><creatorcontrib>Petrusevich, Danila A</creatorcontrib><creatorcontrib>Nedorubov, Andrey A</creatorcontrib><creatorcontrib>Appolonova, Svetlana A</creatorcontrib><creatorcontrib>Moskaleva, Natalia E</creatorcontrib><creatorcontrib>Demina, Natalia B</creatorcontrib><creatorcontrib>Kosenkova, Svetlana I</creatorcontrib><creatorcontrib>Parshenkov, Mikhail A</creatorcontrib><creatorcontrib>Krasnyuk, Jr, Ivan I</creatorcontrib><creatorcontrib>Krasnyuk, Ivan I</creatorcontrib><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mikhel, Iosif B</au><au>Bakhrushina, Elena O</au><au>Petrusevich, Danila A</au><au>Nedorubov, Andrey A</au><au>Appolonova, Svetlana A</au><au>Moskaleva, Natalia E</au><au>Demina, Natalia B</au><au>Kosenkova, Svetlana I</au><au>Parshenkov, Mikhail A</au><au>Krasnyuk, Jr, Ivan I</au><au>Krasnyuk, Ivan I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of an Intranasal In Situ System for Ribavirin Delivery: In Vitro and In Vivo Evaluation</atitle><jtitle>Pharmaceutics</jtitle><addtitle>Pharmaceutics</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>16</volume><issue>9</issue><spage>1125</spage><pages>1125-</pages><issn>1999-4923</issn><eissn>1999-4923</eissn><abstract>Recently, ribavirin has demonstrated effectiveness in treating glioblastoma through intranasal administration utilizing the nose-to-brain delivery route. Enhancing ribavirin's bioavailability can be achieved by utilizing intranasal stimuli-responsive systems that create a gel on the nasal mucosa. The research examined thermosensitive, pH-sensitive, and ion-selective polymers in various combinations and concentrations, chosen in line with the current Quality by Design (QbD) approach in pharmaceutical development. Following a thorough assessment of key parameters, the optimal composition of gellan gum at 0.5%, Poloxamer 124 at 2%, and purified water with ribavirin concentration at 100 mg/mL was formulated and subjected to in vivo testing. Through experiments on male rats, the nose-to-brain penetration mechanism of the active pharmaceutical ingredient (API) was elucidated, showcasing drug accumulation in the olfactory bulbs and brain.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39339163</pmid><doi>10.3390/pharmaceutics16091125</doi><orcidid>https://orcid.org/0000-0002-2866-0049</orcidid><orcidid>https://orcid.org/0009-0004-7170-8783</orcidid><orcidid>https://orcid.org/0000-0002-9032-1558</orcidid><orcidid>https://orcid.org/0000-0001-9337-5917</orcidid><orcidid>https://orcid.org/0000-0002-7309-8913</orcidid><orcidid>https://orcid.org/0000-0001-8557-8829</orcidid><orcidid>https://orcid.org/0000-0001-8695-0346</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 1999-4923
ispartof	Pharmaceutics, 2024-09, Vol.16 (9), p.1125
issn	1999-4923 1999-4923
language	eng
recordid	cdi_doaj_primary_oai_doaj_org_article_21faad652b6d403e958ace4327e26340
source	Publicly Available Content (ProQuest); PubMed Central; Coronavirus Research Database
subjects	Animal experimentation anticancer therapy Bioavailability Brain cancer Brain tumors cancer Cancer therapies Drug development Drug dosages Foreign bodies in situ systems Instrument industry intranasal administration Nose nose-to-brain mechanism Phase transitions Polymers Polysaccharides Ribavirin Tumors
title	Development of an Intranasal In Situ System for Ribavirin Delivery: In Vitro and In Vivo Evaluation
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T23%3A29%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20an%20Intranasal%20In%20Situ%20System%20for%20Ribavirin%20Delivery:%20In%20Vitro%20and%20In%20Vivo%20Evaluation&rft.jtitle=Pharmaceutics&rft.au=Mikhel,%20Iosif%20B&rft.date=2024-09-01&rft.volume=16&rft.issue=9&rft.spage=1125&rft.pages=1125-&rft.issn=1999-4923&rft.eissn=1999-4923&rft_id=info:doi/10.3390/pharmaceutics16091125&rft_dat=%3Cgale_doaj_%3EA810779082%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d405t-c455889cec32793f65473409d36a72f4304a8d939ab4d7c6a713d81e04022d213%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3110649238&rft_id=info:pmid/39339163&rft_galeid=A810779082&rfr_iscdi=true